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Cardiomyocyte proliferation, a target for cardiac regeneration☆
Sandy M. Payan, Fabien Hubert, Francesca Rochais⁎
Aix-Marseille Univ, INSERM, MMG, U 1251, Marseille, France
A B S T R A C T
Cardiac diseases, characterized by cardiomyocyte loss, lead to dramatic impairment of cardiac function and ultimately to congestive heart failure. Despite significant
advances, conventional treatments do not correct the defects in cardiac muscle cell numbers and the prognosis of congestive heart failure remains poor. The
existence, in adult mammalian heart, of low but detectable cardiomyocyte proliferative capacities has shifted the target of regenerative therapy toward new
therapeutical strategy. Indeed, the stimulation of terminally differentiated cardiomyocyte proliferation represents the main therapeutic approach for heart re-
generation. Increasing evidence demonstrating that the loss of mammalian cardiomyocyte renewal potential shortly after birth causes the loss of regenerative
capacities, strongly support the hypothesis that a detailed understanding of the molecular mechanisms controlling fetal and postnatal cardiomyocyte proliferation is
essential to identify targets for cardiac regeneration. Here, we will review major developmental mechanisms regulating fetal cardiomyocyte proliferation and will
describe the impact of the developmental switch, operating at birth and driving postnatal heart maturation, on the regulation of adult cardiomyocyte proliferation, all
these mechanisms representing potential targets for cardiac repair and regeneration.
1. Introduction
Cardiovascular diseases are the leading cause of mortality in in-
dustrialized countries. Despite significant advances conventional
treatments do not replace cardiomyocytes that are lost during the pa-
thology and the prognosis of heart failure remains poor. For this reason,
the replacement of dead cardiomyocytes is becoming the primary target
for regenerative medicine research. The recent discoveries of adult
cardiomyocyte proliferative capacities have orientated cardiovascular
research toward therapeutical strategies that aim to activate adult
cardiomyocyte cell cycle reentry. Although recent studies have un-
covered the regenerative capacity of the newborn mammalian heart,
this regenerative potential is lost shortly after birth, strongly supporting
the hypothesis that a detailed understanding of developmental me-
chanisms is essential to identify targets for cardiac repair and re-
generation.
While certain fishes or amphibians undergo complete adult heart
regeneration following injury [1,2], the adult mammalian heart de-
velops an extensive myocardial scar [3,4]. Nevertheless, mammalian
newborn heart regenerative capacities have been recently uncovered.
Indeed, Porrello et al. demonstrated that 1-day-old postnatal mice are
able to regenerate their myocardium after apex resection and lineage
tracing analysis revealed that neonatal mouse heart regeneration occurs
through partial dedifferentiation and completed cell division of existing
cardiomyocytes. This study nevertheless revealed that mouse heart
postnatal regenerative capacities are lost within the first week of
postnatal life [5]. Interestingly, the loss of mouse postnatal heart re-
generative capacities coincides with decreased cardiomyocyte pro-
liferation as cardiac growth transitions from hyperplasic to hyper-
trophic growth [6]. In addition to postnatal mouse heart regeneration,
multiple evidence of postnatal human heart recovery post-injury have
been reported. In 1937, postmortem histological analysis of a 6 years
old child heart displaying myocardial dilation with necrotic area re-
vealed mitotic cardiomyocytes at the bordure of the injured area sug-
gesting the existence of potential human myocardial regeneration [7].
More recently, a case of a newborn child with massive myocardial in-
farction and subsequent severe cardiac damages has been reported to
undergo complete functional cardiac recovery following myocardial
reperfusion [8]. Postnatal regenerative potential has been also eval-
uated in pigs. Indeed, Zhu et al. demonstrated that the neonatal porcine
heart is also able to regenerate. Notably the authors demonstrated that
pig heart regeneration occurs when cardiomyocyte proliferation levels
are high and is lost when cardiomyocytes exit the cell cycle at postnatal
day 2 [9]. Thus, all these evidence strongly suggest that understanding
the developmental mechanisms controlling cardiomyocyte proliferation
will indisputably lead to the identification of novel targets for pro-
moting adult cardiomyocyte proliferation and ultimately heart re-
generation.
Heart development is a complex process that can be divided in two
main phases of growth. The first phase consists in the addition of
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cardiac progenitors into the heart tube. These cardiac progenitors, lo-
cated outside of the linear embryonic heart tube, are highly pro-
liferative and differentiate as they enter the heart tube in order to
elongate that one. Perturbations in transcriptional regulation and sig-
naling pathways controlling cardiac progenitor deployment will lead to
congenital heart defects [10,11]. The second phase of cardiac growth
occurs at fetal stages. Combined with a remodeling process including
septation of cardiac cavities and outflow track, fetal heart growth is
exclusively achieved through the extensive proliferation of differ-
entiated cardiomyocytes leading to the exponential increase of the
cardiac volumes [12]. Correct morphogenesis of the heart requires a
tight control of fetal cardiomyocyte proliferation, perturbations of
which would lead to congenital heart defects [13].
At fetal stages, cardiomyocyte proliferation is maximal; and at that
stages, cardiomyocytes undergo complete cytokinesis resulting in the
hyperplasic growth of the heart. After birth, a transition from hyper-
plasic to hypertrophic growth is operating, and cardiomyocytes un-
dergo mitosis without cytokinesis resulting in cell binucleation [14,15].
While mouse cardiomyocytes exit the cell cycle approximately one
week after birth [16], the postnatal phase of hyperplasic growth seems
to last for several years in the human heart. Indeed, cardiomyocyte
cytokinesis activity has been detected up to 20 years of age [17].
In contrast to postnatal heart, adult mammalian heart has been, for
decades, considered as post-mitotic. However, several studies have
demonstrated that adult cardiomyocytes are able to replicate their DNA
[18]. More recently, Bergmann et al., taking advantage of the integra-
tion of 14C generated by bomb testing during the Cold War, revealed the
evidence of low but detectable level of cardiomyocyte renewal in
human adult heart with an estimated turnover from 1% to 0.3% per
year [19]. In addition, 15N isotope imaging approach, combined with
genetic-lineage tracing study, clearly demonstrated that in mice, car-
diomyocyte renewal during normal aging is achieved through complete
cell division of pre-existing cardiomyocytes [20]. Altogether, these
studies strongly demonstrate cardiomyocyte renewal throughout life
and support the hypothesis that cardiomyocyte cell cycle reentry and
division could be enhanced in the adult injured heart to promote car-
diac regeneration. Nevertheless, this strategy requires the under-
standing of, on one hand, the molecular mechanisms promoting fetal
and postnatal cardiomyocyte cell division, and on the other hand, those
resulting in postnatal cardiomyocyte cell cycle exit.
Birth is characterized by multiple physiological and morphological
changes that contribute to intense cellular remodeling including in-
creased oxygen consumption associated with metabolic changes [21],
modifications in the extracellular matrix composition [22] and pro-
found transcriptional remodeling [6], that are known now to deeply
contribute to the decrease in cardiomyocyte proliferation after birth.
Here we will review the molecular mechanisms controlling cardio-
myocyte proliferation at fetal stages and will describe the impact of the
developmental switch driving postnatal heart maturation on the reg-
ulation of adult cardiomyocyte proliferation, all these mechanisms re-
presenting potential targets for promoting adult heart regeneration. We
will particularly focus on the role of cell cycle components, the Hippo
pathway, O2 exposure associated with metabolism changes, extra-
cellular matrix (ECM) and growth factors in the control of cardiomyo-
cyte proliferation.
2. Cell cycle component regulation
The cell cycle can be divided into four different phases (G1-G2-S-M)
that are specifically and tightly regulated by cyclins, cyclin-dependent
kinases (CDK) and cyclin-dependent kinase inhibitors (CDKi). After
birth, cardiomyocytes stop proliferating and exit from the cell cycle.
The evaluation of cell cycle regulator expression patterns at fetal and
postnatal stages led to a better understanding of cardiomyocyte cell
cycle exit after birth [6] (Fig. 1). Ikenishi et al. demonstrated that cyclin
and CDK expression, together with their complex formation and
activation, evolve in a synchronous manner at fetal and postnatal
stages. While elevated expression levels of cyclin E, A, B1 and D1 and
CDK1, 2 and 4 and complex formation and activation are observed at
fetal stages, they gradually decrease to reach a minimum level at
postnatal day (P) 0 [23]. The decreased cyclin and CDK expression and
the enhanced inactivation of the cyclin-CDK complex observed after
birth are accompanied by increased expression of CDKi including
p21cip1 and p27kip1 strongly participating to cardiomyocyte cell cycle
exit [24,25]. FOXO transcription factors are known to regulate the
expression of the Cip/Kip family of CDKi. Foxo1 and Foxo3 are ex-
pressed in the developing heart and at neonatal stages. In the adult
heart, while Evans-Anderson et al. described low Foxo1 mRNA levels
and did not detect Foxo3 mRNA [26], substantial levels of myocardial
FOXO3 protein have been reported [27]. In a non-phosphorylated form,
FOXO transcription factors translocate to the nuclei where they tran-
scriptionally activate CDKi expression, leading to decreased cardio-
myocyte proliferation. The IGF1/PI3K/AKT and FGF10 signaling
pathways, by mediating FOXO1 and FOXO3 phosphorylation, respec-
tively, promote embryonic cardiomyocyte proliferation [26,28]. Phos-
phorylated FOXO1 levels gradually decline after E18.5, coinciding with
the increase in p27Kip1 and p21Cip1 expression [25,26]. Conditional
overexpression of a constitutive active form of FOXO1 in fetal heart
results in a thin myocardium, reduced cardiomyocyte proliferation and
early fetal lethality. In contrast, conditional overexpression of a domi-
nant negative form of FOXO1 activity in fetal cardiomyocytes leads to
aberrant cardiomyocyte proliferation consistent with decreased CDKi
expression [26]. The transcription factor MEIS1 through the activation
of CDKi expression including p15, p16 and p21 has been shown to
participate to postnatal cardiomyocyte cell cycle exit. Indeed, MEIS1
which expression increases at P1, switches localization from a peri-
nuclear region at P1 to a nuclear localization at P7. Meis1 deletion in
cardiomyocytes is sufficient to extend the postnatal proliferative
window and promotes cardiomyocyte mitosis in the adult heart [29].
All these studies suggest that the modulation of cell cycle regulator
expression at adult stage may promote cardiomyocyte proliferation and
may be beneficial in pathological conditions.
Conditional overexpression of cyclin D1 in the myocardium pro-
motes cardiomyocyte DNA synthesis and multinucleation in adult heart
[30] and the overexpression of the specific cyclin D2 is sufficient to
promote cardiomyocyte proliferation and improved heart function fol-
lowing myocardial infarction [31,32]. More recently, by increasing the
level of cyclin B-CDK1 and cyclin D-CDK4 complexes, Mohamed et al.
demonstrated that P7 as well as adult cardiomyocytes exhibit enhanced
proliferative rate with complete cytokinesis. Finally, intra-myocardial
injection of this cyclin-CDK cocktail post-myocardial infarction leads to
increased cardiomyocyte proliferation and reduced scar formation as-
sociated with improved cardiac function [33]. All these evidence thus
demonstrate that modulating cell cycle components is thus a promising
strategy to promote cardiomyocyte cell-cycle reentry in the injured
heart.
3. Hippo pathway
The Hippo pathway is a conserved mechanism that restrains cell
proliferation in order to control organ size. The Hippo pathway consists
in a series of kinase cascade activation leading to the phosphorylation
and inactivation of two transcriptional coactivators, named YAP and
TAZ. When activated, YAP and TAZ bind to specific transcription fac-
tors including TEAD, resulting in the positive transcriptional regulation
of genes implicated in cell cycle progression [34]. The Hippo signaling
pathway also controls mammalian heart size. Indeed, the inhibition of
the Hippo component Salvador, during heart development, leads to an
increased cardiomyocyte proliferation resulting in cardiomegaly [35].
YAP expression is robust during development, in neonatal and juvenile
heart but declines with age and is almost undetectable after 12 weeks of
age [36] strongly correlating with its essential role in promoting fetal
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cardiomyocyte proliferation [37]. Indeed, cardiomyocyte-specific Yap
loss of function mouse model substantially reduces fetal cardiomyocyte
proliferation, leading to lethal cardiac hypoplasia at E16.5 [36]. FAT4,
a protocadherin member, has been shown to modulate, through a non-
canonical manner, the Hippo pathway to restrict heart growth. Indeed,
by sequestering the Yap/AMOTL1 complex out of the nucleus, FAT4
prevents cardiomyocyte proliferation [38].
Small noncoding RNAs (miRNAs) regulate gene expression at the
post-transcriptional level by degrading their mRNA targets. To date,
multiple miRNAs have been identified to control both fetal cardio-
myocyte proliferation and postnatal cardiomyocyte cell cycle reentry
[39,40], partly through repression of Hippo core pathway components
[41]. In vitro and in vivo experiments demonstrate that, by upregulating
cell cycle gene expression including cyclin A2, cyclin B1 and CDK1,
YAP gain of function is able to promote adult cardiomyocyte cell cycle
reentry [36]. In addition, the modulation of Hippo pathway compo-
nents including Salvador and YAP is sufficient to enhance postnatal and
adult heart regeneration [40–45]. These evidence thus strongly support
the Hippo pathway as a potential target to promote heart regeneration
and repair (Fig. 2).
4. Oxygen exposure and metabolism
At birth, mammalian heart transitions from a low oxygen environ-
ment to an oxygen rich environment leading to a dramatic metabolic
switch [21]. Indeed, the setting-up of breathing results in the lung
bypass closure (foramen oval and the ductus arteriosus) causing a rapid
raise in O2 pressure in the aorta and an increased cardiac workload. To
support these hemodynamic changes, profound cellular remodeling
including maturation and hypertrophy of cardiomyocytes is essential
[46]. These postnatal cellular changes require high energy production
which will be provided by major rearrangements of energy metabolism
switching from anaerobic glycolysis to oxygen-dependent mitochon-
drial oxidative phosphorylation [47] (Fig. 1). Glycolytic metabolism
has been recently suggested to contribute to the hyperplasic cardiac
growth. Indeed, glucose prevents human embryonic stem cell-derived
cardiomyocyte maturation and promotes their proliferation. Interest-
ingly, a drastic glucose uptake decline is observed at late gestation and
after birth leading to intracellular glucose deprivation [48]. The post-
natal metabolic switch increases ROS production, mitochondrial DNA
content and DNA damage response leading to cardiomyocyte cell cycle
arrest and maturation. Recently, Mills et al., using a cardiac organoid
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culture system, showed that switching metabolism from carbohydrates
to fatty acids is a critical driver of cardiac maturation. Surprisingly, this
proliferative barrier imposed by fatty acid metabolism could be re-
moved by simultaneous activation of both β-catenin and YAP1 [49].
Interestingly, the maintenance of hypoxic conditions after birth
leads to the prolongation of the cardiomyocyte proliferation postnatal
window [50]. The Hypoxia Induced Factor 1α (Hif1α), the master
transcriptional regulator of the adaptive response to hypoxia, has been
strongly suggested to contribute to the regulation of fetal cardiomyo-
cyte proliferation. At fetal stage, the low oxygen environment results in
high Hif1α activity [51], and in addition to regulate gene expression
involved in cardiomyocyte glycolytic status, Hif1α, has been shown to
directly repress genes encoding cell cycle inhibitor including p21 and
p57 and thus promotes proliferation [52]. Consequently, Hif1α mutant
embryos display underdeveloped heart with myocardial hypoplasia due
to a significant decrease in fetal cardiomyocyte proliferation [52,53]. At
birth, mammalian heart transitions from a fetal hypoxic environment to
a postnatal oxygen rich environment, leading to the inhibition of Hif1α
activity [54]. However, in the adult heart, a rare population of hypoxic
cardiomyocytes (Hif1α-responsive) remains. These hypoxic cardio-
myocytes show typical features of proliferative cardiomyocytes in-
cluding low oxidative DNA damage, smaller cell size, and mono-
nucleation [55]. By displaying decreased Meis family member gene
expression and upregulated levels of CDK/cyclins along with the
downregulated expression of negative cell cycle regulators, the hypoxic
cardiomyocytes predominantly contribute to cardiomyocyte renewal
throughout life [55].
Patient and animal models with myocardial infarction, due to re-
duced oxygen availability in the ischemic region, present fetal meta-
bolic gene re-expression causing the reversion of the energy metabolism
from an oxygen-dependent mitochondrial oxidative phosphorylation to
an anaerobic glycolysis [56–58]. This metabolic switch occurs ex-
tremely rapidly following myocardial infarction [59] and coincides
with endogenous upregulation of cardiomyocyte proliferation [60].
Interestingly, the enhanced cardiomyocyte proliferation following
myocardial infarction partly results from the significant increase in the
number of cycling hypoxic cardiomyocytes [55]. Nevertheless, this
endogenous response to hypoxia is not sufficient to face severe myo-
cardial damages caused by the pathology [59]. All these evidence thus
suggest that the modulation of the oxygen environment and subse-
quently metabolism may trigger cardiomyocyte cell-cycle reentry re-
sulting in improved cardiac function and remodeling.
In 2002, Liao et al. showed that increasing myocardial glucose up-
take protects against the progression to heart failure and improves
survival in mice with chronic pressure overload [61]. Nakada et al.
demonstrated that hypoxia exposure one week after the induction of
myocardial infarction leads to an improved heart function associated
with an increased cardiomyocyte proliferation and a decreased fibrosis
deposition, highlighting a potential therapeutic role of hypoxia for
heart regeneration [62]. The transcription factor Pitx2 is expressed in
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the developing embryo soon after gastrulation [63] and is crucial for
regulating cardiac left-right asymmetry during development [64]. By
limiting ROS production after myocardial infarction, Pitx2-gain-of-
function in adult cardiomyocytes has been shown to promote cardiac
regeneration. In this study, Pitx2-induced cardiac regeneration requires
physical PITX2 interaction with YAP in order to cooperatively activate
ROS scavengers [65]. In addition, PITX2 has been recently reported to
be required to maintain, during heart regeneration, proper mitochon-
drial structure and function [66]. Overall these studies highlight the
importance of environmental O2 contents and subsequently metabolism
status in the regulation of cardiomyocyte proliferation and ultimately
heart regeneration (Fig. 2).
5. Extracellular matrix and cell adhesion
Adult cardiomyocytes are highly differentiated cells. Characterized
by a rigid myoskeleton formed by organized sarcomeric structures,
cardiomyocytes are tightly connected with each other through desmo-
somes, adherens, tight and gap junctions [67]. Thus, the extremely
stiffened adult cardiomyocyte, to proceed complete cell cycle, has been
shown to require partial dedifferentiation characterized by the dis-
organization of sarcomere structure and cell adhesion [39,68–70].
Cardiac fibroblasts which primary function is to produce structural
proteins that comprise the extracellular matrix (ECM) [71], seem to
play important role in the regulation of cardiomyocyte proliferation.
Indeed, the composition and stiffness of the ECM surrounding cells is
known to influence cardiomyocyte structure, fate and proliferative ca-
pacities [22,72]. While fetal and early neonatal heart ECM, enriched in
fibronectin and periostin, is pro-proliferative and favors cardiomyocyte
dedifferentiation [73,74], adult heart ECM, enriched in collagen 1,
leads to more organized and non-proliferative cardiomyocytes (Fig. 1)
[22]. In addition, while neonatal cardiomyocytes cultured on rigid
matrix display increased nuclear division without cytokinesis and in-
creased differentiation levels, neonatal cardiomyocytes cultured on soft
matrix display dedifferentiation features including disorganized sarco-
mere network, smaller and rounding cardiomyocytes and cell cycle
reentry [75]; strongly suggesting that extracellular matrix (ECM) re-
modeling may play a crucial role in the regulation of cardiomyocyte cell
cycle progression. Recently, Bassat et al. discovered that ECM compo-
sition from P1 and P7 hearts have distinct properties regarding cardi-
omyocyte proliferation. Indeed, they demonstrated that P1 but not P7
ECM fragments lead to an increased cardiomyocyte proliferation sug-
gesting that, rapidly after birth, modifications in ECM composition may
participate to the loss of cardiomyocyte proliferation and subsequently
loss of regenerative capacities [76]. In particular, they identified Agrin
as a major ECM component. Indeed, Agrin through the disassembly of
the dystrophin–glycoprotein complex (DGC) that sequesters YAP into
the cytoplasmic compartment induces the activation of a YAP-related
signaling mechanism which ultimately promotes cardiomyocyte partial
dedifferentiation and proliferation [76,77] (Fig. 2). In addition to the
modulation of the ECM composition, multiple lines of evidence suggest
that the fibroblast-cardiomyocyte dialog is essential for the regulation
of fetal cardiomyocyte proliferation. Indeed, though paracrine me-
chanisms, cardiac fibroblasts promote fetal cardiomyocyte proliferation
and thus participate to fetal heart growth [73,78]. The adherens junc-
tion protein, α-catenin, has been also shown to play a role in cardio-
myocyte maturation and proliferation. In fact, α-catenin deletion leads
to an increased cardiomyocyte proliferation through the nuclear
translocation of YAP both in perinatal and adult hearts [79] (Fig. 2).
Heart diseases are associated with a massive ECM remodeling re-
sulting in an extensive non-conductive scar formation increasing matrix
rigidity and reducing electrical property that ultimately impairs cardiac
function [80]. Unlike mammals, lower vertebrates including zebrafish
are able to proceed complete heart regeneration after injury. Never-
theless, in contrast to mammalian heart, the massive fibrotic scar de-
veloped in the zebrafish heart after damage is progressively resolved
prior to complete myocardial regeneration [81]. Recent evidence sug-
gest that in the injured zebrafish heart, while fibrotic scar elimination is
required for complete heart regeneration, fibroblast-derived signals are
essential for cardiomyocyte proliferation. Indeed, the ablation of ECM-
producing cells in the injured zebrafish heart dramatically impairs
cardiomyocyte proliferation [82]. Modifications in the ECM composi-
tion of the mouse infarcted heart, through the single intramyocardial
injection of Agrin, were sufficient to improve cardiac function and
promote heart regeneration [76]. However, while dystrophin loss of
function mouse model failed to regenerate following apex resection of
the neonatal heart, compound mutants with Salvador loss of function
(Hippo pathway component) led to efficient cardiac repair [77]
strongly suggesting that Agrin may not only act through the dis-
assembly of DGC complex but may also directly prevent YAP phos-
phorylation. Thus, all these evidence strongly suggest that in patholo-
gical conditions, the modulation of the ECM composition, leading to a
more compliant cardiomyocyte microenvironment, may be essential to
promote cardiomyocyte cell cycle reentry and heart regeneration.
6. Growth factors
Due to their direct action on multiple cellular functions including
cell adhesion, proliferation, differentiation and migration, the role of
growth factors in the regulation of cardiomyocyte proliferation has
been extensively studied. Diverse fibroblast growth factors (FGF) have
been implicated in the regulation of fetal and neonatal cardiomyocyte
proliferation. Indeed, in vitro experiments showed that FGF1, in com-
bination with p38 MAP kinase inhibition [83,84], or FGF2 treatment
[85], promote postnatal cardiomyocyte proliferation. FGF9, FGF16, and
FGF20 signals originating from the endocardium and the epicardium
have been shown to regulate fetal cardiomyocyte proliferation [86–88].
FGF10, which expression gradually declines after birth (Fig. 1) and
coincides with postnatal decreased cardiomyocyte proliferation, has
been reported to specifically regulate, through the phosphorylation of
FOXO3 and the inhibition of p27Kip1 expression, fetal cardiomyocyte
proliferation [28]. Insulin-like growth factors (IGF) which are expressed
by embryonic epicardial cells also play a role in cardiomyocyte pro-
liferation [89]. In vitro and in vivo experiments demonstrate that both
IGF1 and IGF2, through the activation of the PI3K/AKT downstream
signaling cascade, stimulate the proliferation of fetal cardiomyocytes
[26,90,91]. The Neuregulin 1 (NRG1) growth factor and its specific
tyrosine kinase receptors, ErbB2/4, have been described to promote,
through the activation of the PI3K downstream signaling, postnatal
mononucleated cardiomyocyte proliferation [68,92]. Interestingly, po-
tential role of the PI3K signaling pathway in the activation of YAP ac-
tivity [93,94] may suggest that growth factor control of cardiomyocyte
cell cycle progression might involve the Hippo block removal (Fig. 2).
The NRG1/ErbB2/4 signaling induces adult cardiomyocyte cell-
cycle reentry [92] and the constitutively active form of the NRG1 re-
ceptor ErbB2, due to extensive cardiomyocyte proliferation, leads to
cardiomegaly in adult heart [68]. As described above, the epicardial
layer, by providing growth factors as mitogens contributes to myo-
cardial growth during development. In vitro experiments demonstrated
that adult epicardial-derived cell conditioned media increases the pro-
liferation of adult cardiomyocytes and identified the Follistatin-like-1
(FSTL1) protein as an epicardial mitogenic factor [95]. Finally, FGF10
overexpression in adult heart leads to an increased cardiomyocyte
proliferation [28]. All these lines of evidence demonstrating that
growth factors not only enhance fetal cardiomyocyte proliferation but
also promote adult cardiomyocyte cell cycle reentry, strongly suggest
that growth factors may represent putative targets to promote cardiac
regeneration in the injured heart.
After myocardial infarction, FGF1/p38 inhibitor injection enhances
proliferation of both cardiomyocytes and endothelial cells resulting in
improved heart function [83]. FGF2 overexpressing mice display en-
hanced fibroblast and endothelial cell proliferation and cardiomyocyte
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hypertrophy leading to a preserve ejection fraction following myo-
cardial infarction [85]. The administration of IGF1 after ischemia/re-
perfusion decreases cardiomyocyte cell death, prevents cardiac fibrosis
and preserves cardiac function [96,97]. The application, in myocardial
infarcted heart, of FSTL1-loaded patches mimicking epicardial recon-
stitution leads to an improved cardiac function with a decreased fi-
brosis, increased vascularization and cardiomyocyte regeneration [95].
Finally, NRG1 administration or constitutive activation of the NRG1
receptor ErbB2 following myocardial infarction leads to an improved
cardiac function associated with decreased infarct size and increased
cardiomyocyte proliferation [68,92]. All these lines of evidence de-
monstrating the crucial role of growth factors in regulating both fetal
and adult cardiomyocyte proliferation and their beneficial effect after
injury on heart function further support their use for cardiac re-
generative therapeutical strategies.
7. Conclusions
Uncovering the molecular mechanisms controlling cardiomyocyte
proliferation in the fetal heart and identifying the impact of cardiac
morphological and physiological changes that operate at birth on those
molecular determinants have not only enable to better understand
cardiomyocyte cell cycle exit but clearly led to unveil potential targets
for cardiac regeneration and repair. Heart diseases not only result in
severe loss of cardiomyocytes but also display profound remodeling,
including dramatic fibrosis deposition. As reviewed here, multiple
studies revealed that favoring cardiomyocyte renewal post-injury is
sufficient to reduce scar formation. Whether the molecular mechanisms
employed to promote cardiomyocyte cell cycle reentry directly influ-
ence cardiac fibroblast activation has not been elucidated. The emer-
gence of adeno-associated virus (AAV) technologies [98] may be a
valuable strategy to genetically promote cardiomyocyte proliferation in
Human. To date gene therapy for heart failure by using AAV gene
vectors are currently into clinical trials [99,100]. Epicardial patches,
currently used to provide exogenous cardiac cells toward the injured
site [101,102], may also represent an interesting option to administrate
paracrine factors known to target key regulators of cardiomyocyte
proliferation [103]. This review highlights the crucial role of diverse
mechanisms including cell cycle regulators, Hippo pathway, oxygen
exposure, energy metabolism, ECM and growth factors in the regulation
of cardiomyocyte proliferation and cardiac regeneration. Interestingly,
a majority of these mechanisms seems to converge on the Hippo sig-
naling pathway (Fig. 2) strongly suggesting that the release of the
Hippo block operating in mature cardiomyocytes is a crucial checkpoint
to enable cardiomyocytes to reenter the cell cycle.
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